Baylor University Medical Center at Dallas (Baylor Dallas) is now home to North Texas’ largest outpatient cancer center. The new Baylor Charles A. Sammons Cancer Center at Dallas opens to the public Saturday, March 26. The 467,000 square-foot facility marks a new era in cancer care for the Dallas-Fort Worth Metroplex and beyond by offering comprehensive services for cancer patients from initial diagnosis through post-recovery. Baylor Dallas, already the leading cancer care provider in North Texas in terms of patients treated and according to Consumer Choice data, now brings together multiple phases of cancer care under one roof.
To view Multimedia news Release, go to http://multivu.prnewswire.com/mnr/baylorhealth/47429/
Two Merck research scientists, Nancy A. Thornberry and Ann E. Weber, Ph.D., will receive the Discoverers Award, the highest honor from the Pharmaceutical Research and Manufacturers of America (PhRMA), during a ceremony tonight at the Liberty Science Center in Jersey City, N.J.
They will be recognized for their leadership in the discovery of JANUVIA®, a once-daily pill that helps patients with type 2 diabetes control glucose in conjunction with diet and exercise. Though women have been part of teams honored with the Discoverers Award in the past, this is the first time in the award’s 24-year history that women alone have won.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phrma/49723/
According to a new report, How Can We Avoid a Stroke Crisis in the Asia-Pacific Region?, urgent coordinated action is needed to avoid millions of preventable strokes, which leave many patients who have atrial fibrillation (AF) both mentally and physically disabled, or dead, every year.
The report, launched today during the 18th Asian Pacific Congress of Cardiology (APCC) by Action for Stroke Prevention, a group of health experts from across the globe, proposes urgent measures to prevent stroke in Asia-Pacific patients with AF, the most common, sustained abnormal heart rhythm and a major cause of stroke. The report’s recommendations are endorsed by 32 leading Asia-Pacific and other global medical societies and patient organizations, reinforcing and recognizing the need for a call to action.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/strikeoutstroke/48909/
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
Close-Up TV News recognizes the NYU Langone Weight Management Program as the country’s premier surgical weight loss facility
The term “morbid obesity” is generally defined as being 100 lbs over the ideal weight or having a Body Mass Index between 35 and 40. Morbid obesity significantly can increase a patient’s risk for diabetes, heart disease and high blood pressure. Unfortunately, for these patients, diet and exercise alone cannot offer a practical solution.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/thinforlife/50245/
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
Royal Philips Electronics (NYSE: PHG, AEX: PHI) today introduced the HomeLox portable liquid oxygen system. The innovative system enables oxygen users to generate and store the liquid form of oxygen in the home setting. The HomeLox system offers users the long-lasting and lightweight characteristics of traditional liquid systems, while freeing them from difficulties of filling and dependence on deliveries associated with conventional systems.
Home oxygen is a critical, life-sustaining medical treatment prescribed to nearly 1.5 million Medicare patients annually who suffer from respiratory illnesses such as chronic obstructive pulmonary disease (COPD).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/philips/45648/
Today’s U.S. healthcare providers face a three-pronged deluge of demands from patients, insurance companies, and the government. To successfully address these new and evolving expectations, members of the medical sector must leverage the capabilities of new wireless technologies – or fall behind their more savvy competitors.
Frost & Sullivan recently published a whitepaper, Mobile Devices and Healthcare: What’s New, What Fits, and How Do You Decide?, which examines the strengths and drawbacks of four major mobile device types – smartphones, tablets, push-to-talk communication devices, and machine-to-machine (M2M) remote medical monitoring devices. Each device category is evaluated for application in three unique environments – the hospital, physician’s office, and the patient’s home. Criteria for selecting a mobility partner are also discussed.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/51532/
Urgent coordinated action from national governments, medical societies and patient organizations is needed to avoid a public health crisis resulting from the tide of preventable strokes that leave many people with atrial fibrillation (AF) mentally and physically disabled or dead, every year. How Can We Avoid a Stroke Crisis in Latin America?, a report from Action for Stroke Prevention – a group of health experts from around the world - reveals the huge economic, social and personal burden of AF-related strokes across the region. Launched today at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 3rd Latin America Conference, the report proposes measures to tackle stroke in patients with AF, the most common, sustained abnormal heart rhythm and a major cause of stroke.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/strikeoutstroke/50549/
CareFusion (NYSE: CFN), a leading global medical technology company, today announced the launch of the ReVel™ ventilator, a new high performance, portable device designed for pediatric to adult (min. 5Kg) patients who require breathing support during transport.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/carefusion/50615/
Raising public awareness of peripheral neuropathic pain (PNP), The Pain Within is a touring exhibition of major European cities which launched today at the 7th congress of the European Federation of IASP Chapters (EFIC) in Hamburg. Top photographer Alex Telfer has worked with patients to capture their experiences in both portraits and visual metaphors for the exhibition, which is sponsored by Astellas Pharma Europe Ltd. It will then tour in other countries in Europe.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/astellastrade/52120/
New research released today to mark European Week Against Pain reveals that, in more than half of cases, peoples’ levels of pain across Europe are not being adequately assessed.
More than half (52%) of European primary care physicians use no form of assessment tool to measure peoples’ levels of pain despite chronic pain affecting 1 in 52 adults across Europe. A study in Finland found that pain is also the reason for 40% of patient visits to a primary care physician each year, with approximately 20% of these patients having experienced their pain for more than 6 months.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/mundipharma/52140/
